Bicalutamide-induced hepatotoxicity: A rare adverse effect

American Journal of Case Reports

Volumn 15, Issue , 2014, Pages 266-270

  Hussain, Salwa ^a   Haidar, Abdallah ^a   Bloom, Robert E ^a   Zayouna, Nafea ^a   Piper, Michael H ^a   Jafri, Syed Mohammed R ^b  

^a PROVIDENCE HOSPITAL   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Drug induced liver injury; Nonsteroidal anti androgens; Prostatic neoplasms

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BICALUTAMIDE; BILIRUBIN; COPPER; FOLIC ACID; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; IRBESARTAN; IRON; RANITIDINE; SIMVASTATIN; TOXIN;

ABDOMINAL AORTA ANEURYSM; AGED; ANOREXIA; BLOOD EXAMINATION; BONE METASTASIS; CASE REPORT; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; CONJUGATED HYPERBILIRUBINEMIA; CORONARY ARTERY DISEASE; COUNCIL FOR INTERNATIONAL ORGANIZATION OF MEDICAL SCIENCES SCALE; DISEASE DURATION; DRUG WITHDRAWAL; EYE JAUNDICE; HEPATITIS B; HUMAN; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LETHARGY; LIVER FUNCTION; LIVER TOXICITY; LOW DRUG DOSE; MALE; MEDICAL HISTORY; METASTASIS; PHYSICAL EXAMINATION; PROSTATE CANCER; RATING SCALE; URINE COLOR; URINE DISCOLORATION; VERY ELDERLY;

EID: 84902962911     PISSN: None     EISSN: 19415923     Source Type: Journal    
DOI: 10.12659/AJCR.890679     Document Type: Conference Paper

References (13)

1. American Cancer Society. Cancer Facts and Figures 2014. Atlanta: American Cancer Society; 2014
2. Beza C, Sánchez Ruiz J, Peracaula Espino F.J, Villanego B.M.I. Drugrelated hepatotoxicity and hepatic failure following combined androgen blockade. Clin Transl Oncol, 2008; 10(9): 591-92
3. Manso G, Thole Z, Salgueiro E et al: A spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system. Pharmacoepidemiol Drug Saf, 2006; 15(4): 253-59
4. Teschke R, Eickhoff A, Schulze J: Drug and herb induced liver injury in clinical and translational hepatology: Causality assessment methods, quo vadis? J Clin Translat Hepatol, 2013; 1: 59-74
5. Fradet Y: Bicalutamide in the treatment of prostate cancer. Expert Rev Anticancer Ther, 2004; 4(1): 37-48
6. McLeod D.G: Tolerability of nonsteroidal anti-androgens in the treatment of advanced prostate cancer. Oncologist, 1997; 2: 18-27
7. Dawson L, Chow E, Morton G: Fulminant hepatic failure associated with bicalutamide. Urology, 1997; 49: 283-84
8. O'Bryant C.L, Flaig T.W, Utz K.J: Bicalutamide-associated fulminant hepatotoxicity. Pharmacotherapy, 2008; 28(8): 1071-75
9. Kolvenbag G, Blackledge G: Worldwide activity and safety of bicalutamide: a summary review. Urology, 1996; 47: 70-79
10. McLeod D.G, Iversen P, See W.A et al: for the Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg plus standard care versus standard care alone for early prostate cancer. BJU Int, 2006; 97: 247-54
11. Blackledge, G.R, Cockshott I.D, Furr B.J: Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer. Eur Urol, 1996; 31: 30-39
12. Kolvenbag G.J, Blackledge G.R: Worldwide activity and safety of bicalutamide: a summary review. Urology 1996; 47(1A Suppl.): 70-79; discussion 80-84
13. Guo J.J, Wigle P.R, Lammers K et al: Comparison of potentially hepatotoxic drugs among major US drug compendia. Res Social Adm Pharm, 2005; 1(3): 460-79